Ebbu continues to push the boundaries of cannabis science with the announcement today of significant new discoveries, never published in the cannabis research literature. Ebbu has built a state-of-the-art cellular pharmacology drug discovery lab with a poly-pharmaceutical approach in order to understand how the different compounds of cannabis work in concert with each other on the mind and body.
“Once again Ebbu is forging new frontiers. Our cellular pharmacology discovery lab is testing individual and combinations of cannabinoids and terpenes on cannabinoid receptors and other targets that interact closely with the endocannabinoid system,” said Jon Cooper, founder and CEO of Ebbu.
Since the late 1990s, thanks to the pioneering research of Raphael Mechoulam and many others, it’s been understood that the building blocks of cannabis (cannabinoids and other compounds) have a greater effect on the body together than when separated into individual compounds. It’s called the “entourage effect.” However, little has been known about exactly how the entourage effect works because, until recently, study in the US has been stymied by the near complete legal prohibition on marijuana and because most international studies have been focused on individual cannabinoids.
“Think of the effect when you combine chocolate and peanut butter; you experience a third taste. The endocannabinoid system works essentially the same way,” remarked Cooper. “We are studying different compounds that when combined will deliver desirable experiences. We believe this groundbreaking work will result in the most consistent and predictable products in the industry.”
“Ebbu has completed the initial pharmacological fingerprinting of CB1 and has nearly completed its analysis of TRPV1,” said Brian Reid, chief scientist at Ebbu. Cannabinoid receptor 1, or CB1, is recognized as the cannabinoid receptor responsible for the main psychoactive effect of cannabis, and TRPV1, the transient receptor potential cation channel subfamily V member 1, also known as the capsaicin receptor and the vanilloid receptor 1, is a very important target for the perception of pain. Mr. Reid further stated, “Our findings are remarkable. We have identified 11 compound combinations that have synergistic or other notable effects on these two receptors.”
Specifically, Ebbu has found:
- 6 terpenes that moderately increase potency of THC at CB1
- 2 terpenes that strongly increase the potency of THC at CB1
- 2 cannabinoids that moderately increase the effect of THC
- 1 cannabinoid that has a unique interaction with THC. It’s both an antagonist and intensifies the effect of THC at CB1.
In addition, Ebbu has uncovered significant results on TRPV1, which is a very important target for the perception of pain. Ebbu found one terpene that synergizes with THC at TRPV1. Our research will continue examining other combinations of cannabinoids and terpenes.
This research is a significant milestone toward the development of Ebbu’s flagship Feelings line that will enable consumers to choose a desired experience when using our Feelings line products, such as Chill, Energy, Create and Bliss, which are planned for launch in 2017.
Originally published as a Press Release by Ebbu